Success Metrics

Active Trials
3(60%)

Phase Distribution

Ph phase_3
1
20%
Ph phase_2
4
80%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting2
Not yet recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
3
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 24 (80.0%)
Phase 31 (20.0%)

Trials by Status

recruiting240%
active_not_recruiting120%
not_yet_recruiting240%

Recent Activity

3 active trials
Showing 5 of 5
active_not_recruitingphase_3

Phase III Study of AK112 for NSCLC Patients

NCT06396065
recruitingphase_2

A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer

NCT07591090
recruitingphase_2

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

NCT07669779
not_yet_recruitingphase_2

A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma

NCT07636772
not_yet_recruitingphase_2

A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)

NCT06684873

Clinical Trials (5)

Showing 5 of 5 trials
NCT06396065Phase 3

Phase III Study of AK112 for NSCLC Patients

Active Not Recruiting
NCT07591090Phase 2

A Phase II Study of AK146D1 Combined With AK112 in Advanced Breast Cancer

Recruiting
NCT07669779Phase 2

A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer

Recruiting
NCT07636772Phase 2

A Phase II Study of AK146D1 Mono or Combined With AK112 in Advanced Urothelial Carcinoma

Not Yet Recruiting
NCT06684873Phase 2

A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN)

Not Yet Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5